Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets.
about
The genetic landscape of Alzheimer disease: clinical implications and perspectivesThe preclinical phase of the pathological process underlying sporadic Alzheimer's diseaseHumanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyThe intersection of amyloid beta and tau at synapses in Alzheimer's diseaseThe fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice.Identification of disulfide cross-linked tau dimer responsible for tau propagationNeuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain.High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.Invited review: Drug development for tauopathies.Prion-like propagation as a pathogenic principle in frontotemporal dementia.Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.Tau protein as a target for Alzheimer's disease management.Cypermethrin Stimulates GSK3β-Dependent Aβ and p-tau Proteins and Cognitive Loss in Young Rats: Reduced HB-EGF Signaling and Downstream Neuroinflammation as Critical Regulators.Small-molecule PET Tracers for Imaging Proteinopathies.Tau peptides and tau mutant protein aggregation inhibition by cationic polyethyleneimine and polyarginine.Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.Neurodegenerative disorders: Neural synchronization in Alzheimer's disease.The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies.Mapping interactions with the chaperone network reveals factors that protect against tau aggregation
P2860
Q26796582-C903DFC9-D14F-45AF-927F-F0DA4069CB0AQ28083428-B530D621-66E9-42CA-8C49-16C16422DF64Q33640390-5EEBED71-99DC-4A4C-BB43-A53004DFFC42Q34054680-9157EB67-AFD1-449D-BC90-7CE29491D709Q35662607-D1CC1B3C-3A43-4D11-9AE0-EDB3F9D3B30EQ36164278-13AC9AD8-02ED-4AAF-A9B3-60B455B5EE64Q36169754-80F434F4-5A4F-42D0-B14A-892C0EFE542FQ36970998-29D82B96-B62F-4D98-936B-ECE705B81B55Q37736091-6A8D45B3-2B96-42B3-88BE-602F043FF28CQ38263698-A053816D-A390-40B3-BAD4-680B6BF16ADDQ38922025-C38A6184-BB98-4360-946F-D78D0B608E02Q38942540-426AD69D-FC88-41F9-95E2-4FE039A11D6DQ40278614-5AF05CF3-E68B-419E-A221-A08ACD0BC149Q41599510-696E147B-FAEC-4DAA-BA1F-B6CBDA5A4820Q47926474-2F2C5DCB-701F-4E19-95DE-123682CAB5A6Q48214662-D6258E32-262D-4741-94B6-E1B226E282BDQ52613291-F448024E-299A-4EDC-9C9D-9E5AC06EAE4BQ53384509-25E848FD-2EA5-4539-9459-CBBEA4027EF5Q54977832-B0F9FCAD-78F1-46B0-BA08-8153743C8298Q55333133-AC521978-541D-49EB-BCB7-DA639A8E2144Q57560752-08F02393-52E5-4FA2-BA38-35243C4F621D
P2860
Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Propagation of tau pathology i ...... of novel therapeutic targets.
@en
type
label
Propagation of tau pathology i ...... of novel therapeutic targets.
@en
prefLabel
Propagation of tau pathology i ...... of novel therapeutic targets.
@en
P2093
P2860
P356
P1476
Propagation of tau pathology i ...... of novel therapeutic targets.
@en
P2093
Amy M Pooler
Manuela Polydoro
Samantha B Nicholls
Susanne Wegmann
P2860
P2888
P356
10.1186/ALZRT214
P407
P577
2013-10-23T00:00:00Z
P5875
P6179
1017784622